Bhagirathbhai Dholaria is an Oncology physician affiliated with Vanderbilt University Medical Center. OpenAlex indexes 321 publications with 5,928 citations (h-index 37); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2220 Pierce Ave
Nashville, TN 37232
Telephone
615-875-9731Provider last certified this registry record 31 Mar 2022.
Clinical trials
- Lazarus: IT Therapy for ICANS
Sponsor: Vanderbilt-Ingram Cancer Center
- Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma
Sponsor: Vanderbilt-Ingram Cancer Center
- Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Sponsor: Vanderbilt-Ingram Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Biotech, Inc.Program year202520 payments
- Acrotech Biopharma Inc.Program year20256 payments
- AstraZeneca UK LimitedProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
44.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor24.2%Valacyclovir100%Part D≥44 patientsShort-acting sulfonamides10.7%Sulfamethoxazole-Trimethoprim100%Part D≥23 patients+ 3 more classes in this area
Cancer & immunology
36.5%Thalidomide Analog17.5%Revlimid52%Lenalidomide24%Pomalyst23%Part D<11 patientsKinase inhibitor9.6%Jakafi100%Part D≥11 patients+ 3 more classes in this area
Metabolism & gastrointestinal
9.7%Serotonin-3 Receptor Antagonist5%Ondansetron Hcl63%Ondansetron Odt38%Part D<11 patientsCorticosteroid2.5%Prednisone100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Overview of approved CAR-T products and utility in clinical practice
Clinical Hematology International
2024 - Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Journal of Clinical Oncology
2024 - ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies
Biology of Blood and Marrow Transplantation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Wei Zheng, MD, PhD, MPH
Vanderbilt University Medical Center
Brian Rini, MD
Vanderbilt University Medical Center
William Schaffner, MD
Vanderbilt University Medical Center
Jordan Berlin, MD
Vanderbilt University Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”